$BMNM

BIMINI CAPITAL MANAGEMENT, INC. (BMNM): Results of Operations and Financial Condition

BIMINI CAPITAL MANAGEMENT, INC. (BMNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_980652.htm EXHIBIT 99.1 ex_980652.htm Exhibit 99.1 BIMINI CAPITAL MANAGEMENT ANNOUNCES Second QUARTER 2026 RESULTS VERO BEACH, Fla., ( August 6, 2026 ) – Bimini Capital Management, Inc. (OTCQX: BMNM), (“Bimini Capital,” “Bimini,” or the “Company”), today announced re

Original reporting
Published Aug 6, 2026, 8:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$BMNM
Bullish
medium confidence
Mentioned
$BMNM
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BMNMBullishMed
01

Why it matters

The 8-K details Q2 and six-month results, including advisory services revenue growth from Orchid and TJIM, while MBS interest income fell after liquidation to fund the TJIM acquisition.

02

Market read

Traders can update near-term expectations for BMNM based on the disclosed quarterly earnings drivers and the ongoing transition from MBS spread income toward advisory fee income.

03

What to watch

MBS interest income declined sharply due to portfolio liquidation for the TJIM acquisition, so future results may depend on whether fee growth fully offsets lower spread income.

Relevance 7/10Novelty 6/10Timing: after-hours filing, results call scheduled for Aug 7, 2026 10:00 AM ET

Background

Bimini Capital Management is an OTC-listed asset manager with an externally managed relationship to Orchid Island Capital and a recent acquisition of 80% of TJIM completed April 1, 2026.

Company-level read

Ticker impact

$BMNMBullishMedium confidence
Context

Bimini reports Q2 2026 net income of $0.4M, advisory revenue growth, and notes TJIM acquisition contribution starting April 1, 2026.

Expected impact

Near-term bias modestly positive if investors focus on advisory fee growth and improved net income versus prior-year quarter.

Evidence & confidence

This is a primary 8-K earnings-style disclosure with multiple line-item changes and a clear operational driver tied to the TJIM acquisition and Orchid equity growth.

Market effects

Adds datapoints on externally managed mortgage REIT-like/BDC-style fee income sensitivity to MBS portfolio size and funding costs.

Limited, primarily affects OTC-listed asset manager sentiment rather than broad regional risk.

Low; commentary references macro rates and MBS conditions but the actionable disclosure is company-specific.

Counterpoint

Net income improvement may be partly offset by higher operating expenses and acquisition-related costs, so the quality of earnings could be questioned.

Key entities

  • Bimini Capital Management, Inc.

    OTCQX-listed company reporting Q2 2026 results and describing drivers including Orchid fee income and TJIM acquisition contribution.

  • Orchid Island Capital, Inc.

    Externally managed by Bimini Advisors; Orchid generated a 6.21% Q2 2026 return and increased average equity.

  • Bimini Advisors, LLC

    Registered investment advisor subsidiary that administers Orchid and earns advisory services revenue.

  • Tom Johnson Investment Management, LLC (TJIM)

    Privately held SEC-registered investment adviser acquired 80% of by Bimini Advisors Holdings on April 1, 2026.

Related articles

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.

$TAPMed

Molson Coors Beverage Company Q2 2026 Earnings Call Summary

Molson Coors reported Q2 2026 volume pressure tied to an energy and inflation shock after conflict in Iran, plus stronger promotions and geopolitical uncertainty in EMEA and APAC. The company reaffirmed FY2026 guidance, citing improving U.S. industry volumes, 1% to 2% annual U.S. price increases, and Midwest Premium aluminum COGS above $130 million, partly hedged. It also outlined a $450 million cost-savings plan and Atomic Brands integration.

$ITTMed

ITT Inc. Q2 2026 Earnings Call Summary

ITT Inc. reported Q2 2026 results driven by 13% organic revenue growth, including 17% at CCT and 21% at Flow Technologies. Full-year organic revenue guidance was raised to 5% to 8% and margin expansion of over 100 bps is expected. Management cited SPX FLOW integration synergies, $71m one-time acquisition costs, and Middle East order delays.